Limits...
Fully integrated biochip platforms for advanced healthcare.

Carrara S, Ghoreishizadeh S, Olivo J, Taurino I, Baj-Rossi C, Cavallini A, de Beeck MO, Dehollain C, Burleson W, Moussy FG, Guiseppi-Elie A, De Micheli G - Sensors (Basel) (2012)

Bottom Line: However, several issues have to be considered in order to succeed in developing fully integrated and minimally invasive implantable devices.Recent advances in the field have already proposed possible solutions for several of these issues.The aim of the present paper is to present a broad spectrum of recent results and to propose future directions of development in order to obtain fully implantable systems for the continuous monitoring of the human metabolism in advanced healthcare applications.

View Article: PubMed Central - PubMed

Affiliation: École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. sandro.carrara@epfl.ch

ABSTRACT
Recent advances in microelectronics and biosensors are enabling developments of innovative biochips for advanced healthcare by providing fully integrated platforms for continuous monitoring of a large set of human disease biomarkers. Continuous monitoring of several human metabolites can be addressed by using fully integrated and minimally invasive devices located in the sub-cutis, typically in the peritoneal region. This extends the techniques of continuous monitoring of glucose currently being pursued with diabetic patients. However, several issues have to be considered in order to succeed in developing fully integrated and minimally invasive implantable devices. These innovative devices require a high-degree of integration, minimal invasive surgery, long-term biocompatibility, security and privacy in data transmission, high reliability, high reproducibility, high specificity, low detection limit and high sensitivity. Recent advances in the field have already proposed possible solutions for several of these issues. The aim of the present paper is to present a broad spectrum of recent results and to propose future directions of development in order to obtain fully implantable systems for the continuous monitoring of the human metabolism in advanced healthcare applications.

Show MeSH

Related in: MedlinePlus

Two possible integrated biochip platforms.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3472872&req=5

f17-sensors-12-11013: Two possible integrated biochip platforms.

Mentions: Fully integrated biochip platforms for advanced healthcare are possible by considering all of the levels considered in this paper, from electro-chemistry, to biocompatibility, to sensor electronics, and eventually the security and privacy of the acquired data. Figure 17 shows a platform that can host two different micro-array biochips for two different applications. In the first case (on the right), several sensors having targets on drug compounds for anti-cancer treatments are on board. By choosing the right isoform of the probe enzymes from the family of cytochromes P450 we can develop a fully integrated platform for point-of-care application on chemotherapy patients. The considered drugs in the example are cyclophosphamide, etoposide, ftorafur, and torsemide, all compounds used in chemotherapy cocktails [253]. Of course, the possibility to monitor the amount of the anti-cancer compounds in the patients' blood provides the tuning and personalization of the therapy on patient's metabolism.


Fully integrated biochip platforms for advanced healthcare.

Carrara S, Ghoreishizadeh S, Olivo J, Taurino I, Baj-Rossi C, Cavallini A, de Beeck MO, Dehollain C, Burleson W, Moussy FG, Guiseppi-Elie A, De Micheli G - Sensors (Basel) (2012)

Two possible integrated biochip platforms.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3472872&req=5

f17-sensors-12-11013: Two possible integrated biochip platforms.
Mentions: Fully integrated biochip platforms for advanced healthcare are possible by considering all of the levels considered in this paper, from electro-chemistry, to biocompatibility, to sensor electronics, and eventually the security and privacy of the acquired data. Figure 17 shows a platform that can host two different micro-array biochips for two different applications. In the first case (on the right), several sensors having targets on drug compounds for anti-cancer treatments are on board. By choosing the right isoform of the probe enzymes from the family of cytochromes P450 we can develop a fully integrated platform for point-of-care application on chemotherapy patients. The considered drugs in the example are cyclophosphamide, etoposide, ftorafur, and torsemide, all compounds used in chemotherapy cocktails [253]. Of course, the possibility to monitor the amount of the anti-cancer compounds in the patients' blood provides the tuning and personalization of the therapy on patient's metabolism.

Bottom Line: However, several issues have to be considered in order to succeed in developing fully integrated and minimally invasive implantable devices.Recent advances in the field have already proposed possible solutions for several of these issues.The aim of the present paper is to present a broad spectrum of recent results and to propose future directions of development in order to obtain fully implantable systems for the continuous monitoring of the human metabolism in advanced healthcare applications.

View Article: PubMed Central - PubMed

Affiliation: École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. sandro.carrara@epfl.ch

ABSTRACT
Recent advances in microelectronics and biosensors are enabling developments of innovative biochips for advanced healthcare by providing fully integrated platforms for continuous monitoring of a large set of human disease biomarkers. Continuous monitoring of several human metabolites can be addressed by using fully integrated and minimally invasive devices located in the sub-cutis, typically in the peritoneal region. This extends the techniques of continuous monitoring of glucose currently being pursued with diabetic patients. However, several issues have to be considered in order to succeed in developing fully integrated and minimally invasive implantable devices. These innovative devices require a high-degree of integration, minimal invasive surgery, long-term biocompatibility, security and privacy in data transmission, high reliability, high reproducibility, high specificity, low detection limit and high sensitivity. Recent advances in the field have already proposed possible solutions for several of these issues. The aim of the present paper is to present a broad spectrum of recent results and to propose future directions of development in order to obtain fully implantable systems for the continuous monitoring of the human metabolism in advanced healthcare applications.

Show MeSH
Related in: MedlinePlus